Open-label extension study
Sponsors
ES Therapeutics Australia Pty Ltd, Lycera Corp.
Conditions
Drug Resistant EpilepsyUlcerative Colitis
Phase 2
A MULTICENTER OPEN-LABEL EXTENSION STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF LYC-30937-EC IN SUBJECTS WITH ACTIVE ULCERATIVE COLITIS
Active, not recruitingNL-OMON42876
Start: 2017-04-19Target: 5Updated: 2024-02-28
Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy
NCT04714996
Start: 2020-10-30End: 2023-12-31Target: 24Updated: 2023-03-02